1.54  0.01 (0.65%)		01-08 16:00
Open: 1.54 High: 1.636 Volume: 862,216		Pre. Close: 1.53 Low: 1.5 Market Cap: 54(M)

Short term
Mid term
Targets	6-month :	2.09	1-year :	2.43
Resists	First :	1.79	Second :	2.08
Pivot price	1.5
Supports	First :	1.32	Second :	1.09
MAs	MA(5) :	1.46	MA(20) :	1.58
	MA(100) :	1.91	MA(250) :	1.88
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	48.1	D(3) :	33.2
RSI	RSI(14): 45.5
52-week	High :	7	Low :	1.12

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ OSTX ] has closed below upper band by 36.8%. Bollinger Bands are 37.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.64 - 1.64	1.64 - 1.65
Low:	1.48 - 1.49	1.49 - 1.5
Close:	1.53 - 1.54	1.54 - 1.55

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

Mon, 05 Jan 2026
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of OS Therapies Incorporated (NYSE American: OSTX) - PR Newswire

Mon, 05 Jan 2026
OS Therapies Provides First Half 2026 Corporate Outlook - TMX Newsfile

Sun, 28 Dec 2025
OS Therapies Incorporated (NYSEAMERICAN:OSTX) Short Interest Up 82.1% in December - MarketBeat

Mon, 15 Dec 2025
OS Therapies (NYSEAMERICAN:OSTX) Earns "Buy" Rating from D. Boral Capital - MarketBeat

Mon, 15 Dec 2025
D. Boral Capital Maintains OS Therapies (OSTX) Buy Recommendation - Nasdaq

Mon, 15 Dec 2025
OS Therapies (NYSE American: OSTX) targets Jan. 2026 BLA after FDA Type C talks - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.